SCHEMBL2813690

SCHEMBL2813690

Cc1cc(C)n(-c2nc(N)cc(-c3cc(N4CCOCC4)ccn3)n2)n1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.69
ADORA1 P30542 8/20 0.69
EGFR P00533 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 3/20 0.46
ALDH1A1 P00352 1/20 0.46
KDM4E B2RXH2 2/20 0.45
MAPT P10636 4/20 0.44
ALOX15 P16050 2/20 0.44
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
MAPK1 P28482 1/20 0.41
RECQL P46063 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CDK1 P06493 1/20 0.40
CDK2 P24941 1/20 0.40
CHEK1 O14757 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814736 0.82 ADORA2A (1.00) ADORA2AADORA1
SCHEMBL2812966 0.81 ADORA2A (0.69) ADORA2AADORA1EGFRSMN1; SMN2HTT
SCHEMBL5016126 0.76 ADORA2A (0.51) ADORA2AADORA1SMN1; SMN2HTTMAPT
SCHEMBL2814655 0.73 ADORA2A (0.58) ADORA2AADORA1SMN1; SMN2HTTALDH1A1
SCHEMBL8012142 0.70 PIK3CA (0.72) EGFRSMN1; SMN2KDM4E
SCHEMBL5017802 0.70 ALDH1A1 (0.58) ADORA2AADORA1SMN1; SMN2HTTALDH1A1
SCHEMBL2814735 0.70 ADORA2A (0.57) ADORA2AADORA1HTTMAPTALOX15
SCHEMBL27904491 0.69 HTT (0.53) ADORA2AADORA1SMN1; SMN2HTTMAPT
SCHEMBL21143648 0.69 HTT (0.55) ADORA2AADORA1EGFRSMN1; SMN2HTT
SCHEMBL31127289 0.69 HTT (0.55) ADORA2AADORA1EGFRSMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
WO-2008116185-A2 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA3, ADORA1, ADORA2A ADORA2A 3/4885ADORA1 2/4885EGFR 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.